Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Aim: Evaluate quality of life (QOL) in patients with advanced non-small cell lung cancer treated with second- or third-line nab-paclitaxel ± durvalumab. Patients & Methods: Longitudinal QOL was assessed using LCSS, EQ-5D-5L, and EORTC QLQ-C30. Results: QOL was generally stable through 8 treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in LCSS (overall constitutional score and 3-item index [nab-paclitaxel + durvalumab]) and EORTC QLQ-C30 (global health status/QOL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EQ-5D-5L domains were stable/improved or completely resolved at least once in 19% to 56% and 9% to 51% of patients, respectively. Conclusion: While QOL trends were promising, additional data are required to support these regimens in this setting. Keywords (maximum of 10): nab-paclitaxel, durvalumab, quality of life, non-small cell lung cancer, Lung Cancer Symptom Scale, EQ-5D-5L, EORTC QLQ-C30

Type

Journal article

Journal

Future Oncology

Publisher

Future Medicine

Publication Date

10/03/2020

Keywords

nab-paclitaxel, durvalumab, quality of life, non-small cell lung cancer, Lung Cancer Symptom Scale, EQ-5D-5L, EORTC QLQ-C30